Literature DB >> 12834273

cGMP-phosphodiesterase activity is up-regulated in response to pressure overload of rat ventricles.

Noriyuki Yanaka1, Yukie Kurosawa, Kouichi Minami, Eri Kawai, Kenji Omori.   

Abstract

Although expression of natriuretic peptides in cardiac tissues is up-regulated in response to pressure overload, no significant change in cGMP level in hypertrophied ventricles was observed. Activities of two cyclic nucleotide phosphodiesterase (PDE) isoforms, Ca2+/calmodulin-stimulated PDE (PDE1) and cGMP-stimulated PDE (PDE2), were significantly higher in rat left ventricles 14 days after aortic banding. The absence of significant changes in PDE1A and PDE2A mRNA levels indicated that the two PDE activities were post-transcriptionally up-regulated. These results suggested that the increased cGMP-PDE activity in response to pressure overload plays an important role in neutralizing cGMP action in cardiac tissue.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12834273     DOI: 10.1271/bbb.67.973

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  18 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 2.  Compartmentalization of beta-adrenergic signals in cardiomyocytes.

Authors:  Yang K Xiang
Journal:  Circ Res       Date:  2011-07-08       Impact factor: 17.367

3.  Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4.

Authors:  F Hubert; M Belacel-Ouari; B Manoury; K Zhai; V Domergue-Dupont; P Mateo; F Joubert; R Fischmeister; V Leblais
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 4.  Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart.

Authors:  Chen Yan; Clint L Miller; Jun-ichi Abe
Journal:  Circ Res       Date:  2007-03-02       Impact factor: 17.367

Review 5.  Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.

Authors:  Grace E Kim; David A Kass
Journal:  Handb Exp Pharmacol       Date:  2017

6.  Phosphodiesterase PDE2 activity, increased by isoprenaline, does not reduce β-adrenoceptor-mediated chronotropic and inotropic effects in rat heart.

Authors:  Alejandro Galindo-Tovar; María Luisa Vargas; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-19       Impact factor: 3.000

Review 7.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

8.  Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II.

Authors:  Walid Mokni; Thérèse Keravis; Nelly Etienne-Selloum; Alison Walter; Modou O Kane; Valérie B Schini-Kerth; Claire Lugnier
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

9.  Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species.

Authors:  Diane T Stephenson; Tim M Coskran; Margaret B Wilhelms; Wendy O Adamowicz; Michele M O'Donnell; Kathleen B Muravnick; Frank S Menniti; Robin J Kleiman; Daniel Morton
Journal:  J Histochem Cytochem       Date:  2009-06-08       Impact factor: 2.479

10.  Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy.

Authors:  Clint L Miller; Masayoshi Oikawa; Yujun Cai; Andrew P Wojtovich; David J Nagel; Xiangbin Xu; Haodong Xu; Vince Florio; Sergei D Rybalkin; Joseph A Beavo; Yiu-Fai Chen; Jian-Dong Li; Burns C Blaxall; Jun-ichi Abe; Chen Yan
Journal:  Circ Res       Date:  2009-09-24       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.